7 months ago
NBIX
AnalystsAndrew S. FeinAndrew S. Fein's Stock Forecasts
AnalystsAndrew S. Fein
Analyst Ranking
Top 10%
#531 out of 5519 analysts
Average Return
+21.52%
Win Rate
57%42 out of 74
Risk vs Reward
Poor
Good
Andrew S. Fein's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Day One Biopharmaceuticals IncDAWN | +271.21% | $5.80 | $21.53 | 2025-08-06 - 2026-04-23 | Buy |
Palvella Therapeutics IncPVLA | +230.08% | $47.30 | $156.13 | 2025-08-15 - 2026-08-14 | Buy |
Liquidia CorpLQDA | +195.23% | $22.86 | $67.49 | 2025-10-06 - 2026-09-23 | Buy |
Palvella Therapeutics IncPVLA | +159.25% | $57.69 | $149.56 | 2025-09-25 - 2026-09-23 | Buy |
Immunovant IncIMVT | +142.68% | $16.12 | $39.12 | 2025-09-04 - 2026-09-03 | Buy |
Andrew S. Fein Analyst Color
Get additional color on Andrew S. Fein's coverage of popular stocks
9 months ago
BCRX
Andrew S. Fein's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Amylyx Pharmaceuticals IncAMLX | 4 | Buy | $55.00 | +82.48% | Maintains | a month ago |
Biogen IncBIIB | 3 | Buy | $251.00 | +10.89% | Maintains | 2 months ago |
Liquidia CorpLQDA | 6 | Buy | $130.00 | +83.23% | Maintains | 2 months ago |
Metavia IncMTVA | 5 | Buy | $20.00 | +1,126.99% | Reiterates | 2 months ago |
Biocryst Pharmaceuticals IncBCRX | 2 | Buy | $32.00 | +275.59% | Maintains | 3 months ago |
Fulcrum Therapeutics IncFULC | 4 | Hold | $3.00 | -20.74% | Downgrades | 4 months ago |
Catalyst Pharmaceuticals IncCPRX | 1 | Hold | $31.50 | +0.03% | Downgrades | 4 months ago |
Wave Life Sciences IncWVE | 5 | Buy | $13.00 | +228.28% | Maintains | 4 months ago |
Madrigal Pharmaceuticals IncMDGL | 4 | Buy | $620.00 | +20.81% | Reiterates | 5 months ago |
Kalvista Pharmaceuticals IncKALV | 1 | Hold | $27.00 | 0.00% | Downgrades | 5 months ago |
Aura Biosciences IncAURA | 1 | Buy | $24.00 | +290.24% | Maintains | 5 months ago |
Protara Therapeutics IncTARA | 1 | Buy | $27.00 | +705.97% | Maintains | 5 months ago |
Neurocrine Biosciences IncNBIX | 3 | Buy | $215.00 | +54.74% | Maintains | 6 months ago |
United Therapeutics CorpUTHR | 3 | Buy | $660.00 | +39.77% | Maintains | 6 months ago |
Insmed IncINSM | 4 | Buy | $245.00 | +101.56% | Maintains | 6 months ago |
Denali Therapeutics IncDNLI | 1 | Buy | $42.00 | +105.18% | Maintains | 6 months ago |
Palvella Therapeutics IncPVLA | 6 | Buy | $270.00 | +84.84% | Maintains | 6 months ago |
Vertex Pharmaceuticals IncVRTX | 4 | Buy | $641.00 | +22.71% | Maintains | 7 months ago |
Savara IncSVRA | 3 | Buy | $10.00 | +97.24% | Maintains | 9 months ago |
Dbv Technologies SaDBVT | 3 | Buy | $40.00 | +244.83% | Maintains | 9 months ago |
Kymera Therapeutics IncKYMR | 3 | Buy | $134.00 | +15.71% | Maintains | 10 months ago |
Kamada LtdKMDA | 1 | Buy | $13.00 | +47.23% | Maintains | 10 months ago |
Arcturus Therapeutics Holdings IncARCT | 3 | Hold | $9.00 | -36.26% | Maintains | 10 months ago |
Prothena Corp Public Ltd CoPRTA | 3 | Buy | $30.00 | +260.58% | Maintains | a year ago |
Akero Therapeutics IncAKRO | 2 | Hold | $54.00 | -1.19% | Downgrades | a year ago |
89bio IncETNB | 2 | Hold | $14.50 | N/A | Downgrades | a year ago |
Terns Pharmaceuticals IncTERN | 1 | Hold | $7.44 | N/A | Assumes | a year ago |
Immunovant IncIMVT | 1 | Buy | $35.00 | N/A | Reiterates | a year ago |
Arvinas IncARVN | 1 | Buy | $18.00 | N/A | Maintains | a year ago |
Day One Biopharmaceuticals IncDAWN | 1 | Buy | $25.00 | N/A | Maintains | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.